[go: up one dir, main page]

WO2000006139A3 - Use of moclobemide and metabolites for treating and preventing substance abuse - Google Patents

Use of moclobemide and metabolites for treating and preventing substance abuse Download PDF

Info

Publication number
WO2000006139A3
WO2000006139A3 PCT/US1999/017275 US9917275W WO0006139A3 WO 2000006139 A3 WO2000006139 A3 WO 2000006139A3 US 9917275 W US9917275 W US 9917275W WO 0006139 A3 WO0006139 A3 WO 0006139A3
Authority
WO
WIPO (PCT)
Prior art keywords
moclobemide
treating
metabolites
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/017275
Other languages
French (fr)
Other versions
WO2000006139A2 (en
Inventor
Donald F Klein
Seth Lederman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tinea Pharmaceuticals Inc
Original Assignee
Janus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janus Pharmaceuticals Inc filed Critical Janus Pharmaceuticals Inc
Priority to MXPA01001180A priority Critical patent/MXPA01001180A/en
Priority to CA002338326A priority patent/CA2338326A1/en
Priority to JP2000561994A priority patent/JP2002521432A/en
Priority to AU52439/99A priority patent/AU5243999A/en
Publication of WO2000006139A2 publication Critical patent/WO2000006139A2/en
Publication of WO2000006139A3 publication Critical patent/WO2000006139A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods and compositions for using moclobemide, a moclobemide metabolite, a moclobemide derivative or a moclobemide composition to assist in treating or preventing physical dependence on, or withdrawal symptoms associated with alcohol and drugs, including opioids, other central nervous system depressants such as sedatives, central nervous system stimulants such as cocaine and amphetamines, and other drugs active upon the central nervous system.
PCT/US1999/017275 1998-07-31 1999-07-30 Use of moclobemide and metabolites for treating and preventing substance abuse Ceased WO2000006139A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MXPA01001180A MXPA01001180A (en) 1998-07-31 1999-07-30 Methods and compositions for treating and preventing substance abuse using moclobemide.
CA002338326A CA2338326A1 (en) 1998-07-31 1999-07-30 Use of moclobemide and metabolites for treating and preventing substance abuse
JP2000561994A JP2002521432A (en) 1998-07-31 1999-07-30 Methods and compositions for the treatment and prevention of substance abuse using moclobemide
AU52439/99A AU5243999A (en) 1998-07-31 1999-07-30 Methods and compositions for treating and preventing substance abuse using moclobemide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9498698P 1998-07-31 1998-07-31
US60/094,986 1998-07-31

Publications (2)

Publication Number Publication Date
WO2000006139A2 WO2000006139A2 (en) 2000-02-10
WO2000006139A3 true WO2000006139A3 (en) 2000-05-04

Family

ID=22248350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017275 Ceased WO2000006139A2 (en) 1998-07-31 1999-07-30 Use of moclobemide and metabolites for treating and preventing substance abuse

Country Status (5)

Country Link
JP (1) JP2002521432A (en)
AU (1) AU5243999A (en)
CA (1) CA2338326A1 (en)
MX (1) MXPA01001180A (en)
WO (1) WO2000006139A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2485954C1 (en) * 2012-02-29 2013-06-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" РАМН Medication for withdrawal syndrome management in opiate dependence
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN113993522A (en) 2019-04-17 2022-01-28 指南针探路者有限公司 Method for treating anxiety disorders, headache disorders and eating disorders with siloxibin
PH12022553135A1 (en) 2020-05-19 2024-03-04 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028934A2 (en) * 1994-04-22 1995-11-02 F. Hoffmann-La Roche Ag Use of mao-a inhibitors for the manufacture of a medicament in the treatment of tobacco withdrawal symptoms in smokers
BR9402744A (en) * 1994-08-12 1996-04-02 Tostes Luiz Roberto Mallat Composition and method for treating alcoholism and composition and method for treating anxiety and / or depression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028934A2 (en) * 1994-04-22 1995-11-02 F. Hoffmann-La Roche Ag Use of mao-a inhibitors for the manufacture of a medicament in the treatment of tobacco withdrawal symptoms in smokers
BR9402744A (en) * 1994-08-12 1996-04-02 Tostes Luiz Roberto Mallat Composition and method for treating alcoholism and composition and method for treating anxiety and / or depression

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TOSTES, LUIZ ROBERTO MALLAT: "Combinations of moclobemide and buspirone and methods for treatment of alcoholism, anxiety, and depression", XP002132561, retrieved from STN Database accession no. 125:214681 *
LEPOLA U.: "Alcohol and depression in panic disorder.", ACTA PSYCHIATRICA SCANDINAVICA, SUPPLEMENT, (1994) 89/377 (33-35)., XP000884640 *
MALLAT-TOSTES L.R.: "[Use of combined moclobemide -buspirone in the treatment of alcohol dependence syndrome]. USO DA ASSOCIACAO MOCLOBEMIDA -BUSPIRONA NO TRATAMENTO DO ALCOOLISMO.", JORNAL BRASILEIRO DE PSIQUIATRIA, (1995) 44/3 (137-142)., XP000884641 *
SOYKA M.: "[Anti- craving substances in the treatment of alcoholism: A new therapeutic challenge]. ANTI- CRAVING -SUBSTANZEN IN DER THERAPIE DER ALKOHOLABHANGIGKEIT - EINE NEUE THERAPEUTISCHE HERAUSFORDERUNG.", SUCHT, (1996) 42/5 (308-309)., XP000884576 *
UZBAY I T ET AL: "Investigation of the effects of moclobemide in chronic ethanol feeding rats.", PHARMACOLOGICAL RESEARCH, (1995 NOV) 32 (5) 287-92., XP000884625 *
VERSIANI M ET AL: "Social phobia: long-term treatment outcome and prediction of response--a moclobemide study.", INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, (1997 SEP) 12 (5) 239-54., XP000884561 *

Also Published As

Publication number Publication date
JP2002521432A (en) 2002-07-16
WO2000006139A2 (en) 2000-02-10
AU5243999A (en) 2000-02-21
MXPA01001180A (en) 2002-04-24
CA2338326A1 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
Peres et al. Tetraoxygenated naturally occurring xanthones
AU559218B2 (en) Improved analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
WO2003018004A3 (en) Analgetic pyrroline derivatives
WO2001068138A3 (en) Intradermal-penetration agents for topical local anesthetic administration
CA2001618A1 (en) Gestodene-containing agent for transdermal administration
IE843166L (en) Pharmaceutical composition - xanthine derivatives
WO2000011971A3 (en) Fiber and vitamin-fortified beverage
WO2002018327A3 (en) Guanidinobenzamides as mc4-r agonists
EP0890359A4 (en)
EP1391200A4 (en) DRUG PREPARATIONS
AU4308397A (en) Substituted 2-pyrimidineamines, their preparation and their use as proteine kinase inhibitors
AR033342A1 (en) A TOPIC OR INTRANASAL OTHICAL COMPOSITION TO TREAT OTICO PAIN AND THE TOPICAL USE OF KAPA OPIOID AGONISTS TO TREAT OTICO PAIN
WO2002002093A3 (en) Combination containing an antifolate and methylmalonic acid lowering agent
WO1999000117A3 (en) Neuroprotective methods and reagents
EP0917873A4 (en) Eyedrops
ZA200000171B (en) Analgesic with controlled active substance release.
IE831715L (en) Analgesic and anti-inflammatory compositions
WO2001034125A3 (en) Therapeutic use and formulation of (-)-tramadol
DE60134645D1 (en) AMIDINE DERIVATIVES AS SELECTIVE NMDA RECEPTOR ANTAGONISTS
EP0974363A4 (en) Remedies for drug addiction
PT839149E (en) GALANTAMINE DERIVATIVES PROCESS OF THEIR PREPARATION ITS APPLICATION AS A MEDICATION AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
WO2000006139A3 (en) Use of moclobemide and metabolites for treating and preventing substance abuse
EP1621207A3 (en) Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors
IE800952L (en) Morphanthridines.
Sanger et al. Evidence for a role for dopamine D3 receptors in the effects of dopamine agonists on operant behaviour in rats

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2338326

Country of ref document: CA

Ref country code: CA

Ref document number: 2338326

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09772678

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001180

Country of ref document: MX

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase